hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06277947, orgStudyIdInfo id: SYSKY-2024-096-01, briefTitle: Administration of Hyperthermic Intraperitoneal Chemotherapy in the General Ward, acronym: GARD-HIPEC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, class: OTHER, collaborators name: Shenshan Medical Center, Memorial Hospital of Sun Yat-sen University, descriptionModule briefSummary: Ovarian cancer is the most lethal gynecologic malignancy. The majority of patients get diagnosed with advanced disease with peritoneal dissemination.It has been demonstrated that the addition of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to interval debulking surgery can improve the prognosis. The National Comprehensive Cancer Network (NCCN) treatment guideline has recommended HIPEC as a first-line treatment for patients with advanced ovarian cancer. However, the guideline recommended the "Dutch model" of HIPEC, which is limited for routinely being performed in China. So we propose a HIPEC treatment modality, the bedside closed HIPEC in the general ward (C-HIPEC), which is suitable for the clinical characteristics of China. The aim of this study was to evaluate the safety of this model as a way to lay the foundation for subsequent efficacy evaluation and clinical promotion., conditionsModule conditions: Epithelial Ovarian Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Patients would receive C-HIPEC in the general ward after interval debulking surgery in 24 hours., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 92, type: ESTIMATED, armsInterventionsModule interventions name: China Hyperthermic Intraperitoneal Chemotherapy(C-HIPEC), outcomesModule primaryOutcomes measure: The incidence of adverse events of grade 3-5, secondaryOutcomes measure: Time to progress (TTP), secondaryOutcomes measure: The Time to the First Subsequent Therapy，TTFST, secondaryOutcomes measure: Quality of life, QLQ-C30, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, city: Guangzhou, country: China, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06277895, orgStudyIdInfo id: KYLL-202401-047, briefTitle: VOCs in Patients With Acute Cardiogenic Chest Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-26, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Qilu Hospital of Shandong University, class: OTHER, descriptionModule briefSummary: The goal of this observation study is to compare VOCs in cardiogenic chest pain population/health conditions, to answer：Establishment and promotion of the application system of emergency rapid detection of expiratory Volatile Organic Compounds (VOCs) in patients with acute cardiogenic chest pain1. VOCs levels were measured at baseline in healthy people, and markers of VOCs that could be used to identify acute cardiogenic chest pain were sought.2. The relationship between abnormal VOCs (mainly aldehydes) and prognosis of patients and the correlation with Super-score for early warning of acute heart failure., conditionsModule conditions: Acute Coronary Syndrome, conditions: Acute Aortic Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 1400, type: ESTIMATED, armsInterventionsModule interventions name: VOCs, outcomesModule primaryOutcomes measure: Baseline VOCs (aldehydes) levels in healthy population, secondaryOutcomes measure: MACE in patients with cardiogenic chest pain, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Qilu hospital, status: RECRUITING, city: Jinan, state: Shandong, zip: 250012, country: China, contacts name: yuan bian, role: CONTACT, phone: 18560084775, email: 15165110975@163.com, geoPoint lat: 36.66833, lon: 116.99722, hasResults: False
protocolSection identificationModule nctId: NCT06277843, orgStudyIdInfo id: PR-21131, briefTitle: Low-Cost and Reusable Thermal Jacket for Managing Preterm or Low Birth Weight Neonates., statusModule overallStatus: COMPLETED, startDateStruct date: 2022-06-13, primaryCompletionDateStruct date: 2022-09-01, completionDateStruct date: 2022-09-30, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: International Centre for Diarrhoeal Disease Research, Bangladesh, class: OTHER, collaborators name: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, collaborators name: Directorate General of Health Services (DGHS), Bangladesh, collaborators name: Poeticgem International Ltd, collaborators name: University of Dhaka, descriptionModule briefSummary: Globally, over 15 million neonates are born preterm each year. They account for approximately 30% of global neonatal deaths and 19% of total neonatal deaths in Bangladesh. They usually die because they cannot maintain normal temperature due to their weight, immature skin and underdeveloped thermal regulatory capacity of the brain.Maintaining continuous KMC for at least 16-20 hours/day, is sometimes not feasible for mothers or caregivers. In addition, we also have the challenge of keeping preterm or LBW neonates warm during transportation.The scientists at icddr,b, Johns Hopkins University, and George Mason University developed the re-usable thermal jacket for keeping preterm or low-birth-weight neonate warm. We propose to build on previous work by systematically testing the safety of the 'thermal jacket' among preterm or low birthweight (LBW) neonates.Objective of this study is to conduct clinical safety trial of the thermal jacket to test whether the thermal jacket can retain euthermia of preterm or LBW neonates for 2 hours., conditionsModule conditions: Preterm, conditions: Low Birthweight, conditions: Hypothermia Neonatal, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Single arm non-randomized trial, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ACTUAL, armsInterventionsModule interventions name: Thermal Jacket, outcomesModule primaryOutcomes measure: Body temperature of preterm or low birthweight neonates and duration of time in euthermic range., eligibilityModule sex: ALL, minimumAge: 0 Hours, maximumAge: 72 Hours, stdAges: CHILD, contactsLocationsModule locations facility: Bangabandhu Sheikh Mujib Medical University (BSMMU), city: Dhaka, zip: 1000, country: Bangladesh, geoPoint lat: 23.7104, lon: 90.40744, hasResults: False
protocolSection identificationModule nctId: NCT06277830, orgStudyIdInfo id: 2023P002788, briefTitle: Physical Activity Monitoring in Myasthenia Gravis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-14, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Massachusetts General Hospital, class: OTHER, collaborators name: BioSensics, descriptionModule briefSummary: The goal of this observational study is to evaluate the feasibility of using wearable sensor and digital technologies to measure motor and speech function in adults with autoimmune Myasthenia Gravis (MG).The main question\[s\] it aims to answer are:* To measure the correlation of sensor-based measures of motor function with existing outcome measures including the MG-ADL, MGQOL15r, QMG, MGComposite, and Neuro-QOL Fatigue scales.* To develop and validate tablet-based digital assessments of speech and facial expression and to compare with existing outcome measures.Participants will wear a pendant sensor for 7 days and then participate in tablet-based and in-person myasthenia-specific physical examinations. This will be performed in concert with routine care in the Massachusetts General Hospital MG clinic., conditionsModule conditions: Myasthenia Gravis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Wearable sensor, outcomesModule primaryOutcomes measure: Primary outcome, secondaryOutcomes measure: Exploratory outcome, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Massachusetts General Hospital, status: RECRUITING, city: Boston, state: Massachusetts, zip: 02114, country: United States, contacts name: Carina Stafstrom, BS, role: CONTACT, email: cstafstrom@mgh.harvard.edu, contacts role: CONTACT, phone: 617-726-5175, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06277804, orgStudyIdInfo id: LTC004-102, briefTitle: A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2027-07-01, completionDateStruct date: 2027-07-01, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Letolab, class: INDUSTRY, descriptionModule briefSummary: This was a multicenter, open PHASE I study of LTC004 in Combination With Cyclophosphamide and Fludarabine in Patients With Advanced/Metastatic Malignancies Tumor, the study design consisting of 2 phases: Phase Ia (Phase Ia dose escalation) and Phase Ib (Phase Ib expansion). The objective of this study was to evaluate combination safety, tolerability, pharmacokinetic,pharmacodynamics characteristics, and initial efficacy in advanced malignant tumors., conditionsModule conditions: Adult Solid Tumor, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: LTC004 in Combination With Cyclophosphamide and Fludarabine, outcomesModule primaryOutcomes measure: Safety, tolerability and antitumor efficacy of Combination., secondaryOutcomes measure: PK Characteristics and immunogenicity of Combination, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06277791, orgStudyIdInfo id: HStomatologyWuhan1, briefTitle: The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-08-19, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2025-07-31, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Hospital of Stomatology, Wuhan University, class: OTHER, descriptionModule briefSummary: The goal of this \[type of study:clinical trial\] is to \[learn about\] in \[Clinical IVB stage oral squamous cell carcinoma patients\]. The main question it aims to answer are:• \[Observing the effectiveness and safety of the combination of Adebrelimab and TP regimen in neoadjuvant therapy for clinical IVB stage oral squamous cell carcinoma patients\] Participants will \[Received treatment with Adebrelimab combined with TP regimen, followed by surgery after 2 cycles of neoadjuvant therapy. After surgery, radiotherapy and chemotherapy combined with immunotherapy were chosen based on the patient\&#39;s condition, with a total follow-up of two years.\]., conditionsModule conditions: Clinical IVb Stage Oral Squamous Cell Carcinomas Patients, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: Adebrelimab, outcomesModule primaryOutcomes measure: Effective mitigation rate（EMR）, secondaryOutcomes measure: DFS, secondaryOutcomes measure: R0 resection rate, secondaryOutcomes measure: ORR, secondaryOutcomes measure: mOS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: School of Stomatology Wuhan University, status: RECRUITING, city: Hubei, state: Wuhan, zip: 430079, country: China, contacts name: JJia Associate Professor, role: CONTACT, phone: +8613277924848, email: junjia@whu.edu.cn, contacts name: zili Yu, role: PRINCIPAL_INVESTIGATOR, hasResults: False
protocolSection identificationModule nctId: NCT06277778, orgStudyIdInfo id: HSEARS20211117003-03, briefTitle: Effect of Combined Music and Taekwondo Training for Children With Autism Spectrum Disorder, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: The Hong Kong Polytechnic University, class: OTHER, descriptionModule briefSummary: The goal of this randomized controlled trial is to evaluate the effect of combined music and taekwondo training on the mental and physical condition of children with autism spectrum disorder. Participants will be asked to do combined music and taekwondo training or taekwondo training alone to evaluate if the combined training is better than the taekwondo training alone on mental and physical performance for children with autism spectrum disorder., conditionsModule conditions: Autism Spectrum Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Taekwondo training with music therapy, interventions name: Taekwondo training alone, outcomesModule primaryOutcomes measure: Engagement in the Training Sessions, primaryOutcomes measure: Gross Motor Skills, secondaryOutcomes measure: Physical Activity Level, secondaryOutcomes measure: Enjoyment State, secondaryOutcomes measure: Rate of Perceived Exertion, secondaryOutcomes measure: Taekwondo skills performance, secondaryOutcomes measure: Conners' Continuous Performance Test II, secondaryOutcomes measure: Comprehensive Trail-Making Test (CTMT), secondaryOutcomes measure: Social Responsiveness Scale, second edition (SRS-2), secondaryOutcomes measure: Childhood Autism Spectrum Test, secondaryOutcomes measure: Strength and Difficulties Questionnaires (SDQ), secondaryOutcomes measure: Clinical Global Improvement (CGI) score, eligibilityModule sex: ALL, minimumAge: 7 Years, maximumAge: 9 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06277765, orgStudyIdInfo id: CM310-101212, briefTitle: Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-30, primaryCompletionDateStruct date: 2025-05-30, completionDateStruct date: 2025-05-30, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Keymed Biosciences Co.Ltd, class: INDUSTRY, descriptionModule briefSummary: This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, PK, PD and immunogenicity of CM310 in children patients with moderate-to-severe atopic dermatitis., conditionsModule conditions: Atopic Dermatitis, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 180, type: ESTIMATED, armsInterventionsModule interventions name: CM310, interventions name: placebo, outcomesModule primaryOutcomes measure: Proportion of subjects achieving EASI-75 at week 18, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Peking University People's hospital, city: Beijing, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06277752, orgStudyIdInfo id: CIBI128A101, briefTitle: A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor), statusModule overallStatus: COMPLETED, startDateStruct date: 2024-03-05, primaryCompletionDateStruct date: 2024-03-16, completionDateStruct date: 2024-03-16, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Innovent Biologics (Suzhou) Co. Ltd., class: INDUSTRY, descriptionModule briefSummary: A Phase I study to evaluate the pharmacokinetic/pharmacodynamic characteristics,safety and tolerability of IBI128 after multidosing in Chinese health subjects., conditionsModule conditions: Gout Arthritis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: dose-5 group, interventions name: dose-1 group, interventions name: dose-2 group, interventions name: dose-4 group, interventions name: dose-3 group, outcomesModule primaryOutcomes measure: PK parameter: Cmax, primaryOutcomes measure: PK parameter: AUC, primaryOutcomes measure: PK parameter: Tmax, primaryOutcomes measure: PK parameter: T1/2, secondaryOutcomes measure: Safety parameter: AE, secondaryOutcomes measure: PD parameter: serum UA (uric acid）, secondaryOutcomes measure: Tolerability parameter: SAE, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: The First Affiliated, city: Zhengzhou, state: Henan, zip: 450000, country: China, geoPoint lat: 34.75778, lon: 113.64861, hasResults: False
protocolSection identificationModule nctId: NCT06277739, orgStudyIdInfo id: 20220117020315695, briefTitle: Brain Effect Mechanism of Spinal Manipulative Therapy on LDH Analgesia Based on Multimodal MRI, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-06-01, primaryCompletionDateStruct date: 2026-09-01, completionDateStruct date: 2026-09-01, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Zhou Xingchen, class: OTHER, descriptionModule briefSummary: The clinical symptoms of Lumbar Disc Herniation (LDH) can be effectively ameliorated through Spinal Manipulative Therapy (SMT), which is closely linked to the brain's pain-regulating mechanisms. Magnetic Resonance Imaging (MRI) offers an objective and visual means to study how the brain orchestrates the characteristics of analgesic effects. From the perspective of multimodal MRI, the investigators applied functional MRI (fMRI) and Magnetic Resonance Spectrum (MRS) techniques to comprehensively evaluate the characteristics of the effects of SMT on the brain region of LDH from the aspects of brain structure, brain function and brain metabolism. This multimodal MRI technique provides a biological basis for the clinical application of SMT in LDH., conditionsModule conditions: Lumbar Disc Herniation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Spinal Manipulative Therapy, interventions name: Sham Laser Treatment, outcomesModule primaryOutcomes measure: visual analogue scale (VAS), primaryOutcomes measure: Japanese Orthopaedic Association Scores (JOA), primaryOutcomes measure: Amplitude of Low-Frequency Fluctuation (ALFF), primaryOutcomes measure: Regional Homogeneity (ReHo), primaryOutcomes measure: Functional Connectivity (FC), primaryOutcomes measure: Magnetic Resonance Spectrum （MRS）, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Third Affiliated Hospital of Zhejiang Chinese Medical University, city: Hangzhou, state: Zhejiang, zip: 310053, country: China, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06277726, orgStudyIdInfo id: IU-SBE-CGI-01, briefTitle: The Effect of Two Non-pharmacological Methods on Pain and Anxiety Experienced During Intrauterine Device Application., statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-01, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-04, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Inonu University, class: OTHER, collaborators name: The Scientific and Technological Research Council of Turkey, descriptionModule briefSummary: The purpose of this study is to determine the effect of emotional freedom technique and music, which are effective in relieving pain and anxiety, on the pain and anxiety that occur during intrauterine device application., conditionsModule conditions: Intrauterine Devices, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized controlled study with pre-test post-test group, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, maskingDescription: In order to ensure randomization and prevent contamination between groups, data will be collected in a sequence such that emotional freedom technique is collected one week, music is collected one week, and control group data is collected one week. It will be decided by drawing lots which group's data will be collected first., whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 168, type: ESTIMATED, armsInterventionsModule interventions name: Emotional freedom technique group, interventions name: Music group, interventions name: Control group, outcomesModule primaryOutcomes measure: Visual Analog Scale (VAS), primaryOutcomes measure: State Anxiety Inventory, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 49 Years, stdAges: ADULT, contactsLocationsModule locations facility: Şırnak State Hospital, status: RECRUITING, city: Şırnak, zip: 73000, country: Turkey, contacts name: Ceylan GÜZEL İNAL, Lecturer, role: CONTACT, phone: +095432588644, email: cylngzl@hotmail.com, geoPoint lat: 37.51393, lon: 42.45432, hasResults: False